Edison Investment Research - Solon Eiendom ASA (SOLON) Update: Prepping for the future; REDUC read-out in H215

Report

Edison Investment Research

Update: Prepping for the future; REDUC read-out in H215

Following encouraging interim data from the Phase II REDUC trial of Vacc-
4x with romidepsin, Bionor has set a number of initiatives in motion to
fully capitalise on the potential opportunity that this â€˜Kick and Killâ€™
approach could offer in HIV. This includes planning next development
steps by convening an expert panel, securing future romidepsin supply
and exploring potential financing options. These endeavours should
ensure that Bionor will be well-placed to swiftly advance Vacc-4x, if further
REDUC data expected in H215 are positive. Our valuation is NOK1bn.

13/08/2015 4 EN

Underlying

Solon Eiendom ASA

Solon Eiendom is a biotechnology company. Co.'s focus is the research and development of peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). As of Dec 31 2013, Co.'s clinical development pipeline comprised of two vaccine candidates for the treatment of HIV, Vacc-4X and Vacc-C5. Vacc-4X is being investigated in two phases II trials in collaboration with Celgene Inc.

See profile

NO0003106700 Oslo Bors Norway

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

ABG Sundal Collier

Solon Eiendom - Terminating coverage

ABGSC terminates coverage of Solon Eiendom… …following its acquisition by SBB Last published estimates are shown in this report

January 17, 2022 January 17, 2022 1 EN

DnB Markets

Changes ahead on the new EU Green Deal White Paper

Green building-code regulations have so far targeted only newbuilds and some large renovations; however, a recent EC White Paper aims to regulate and speed up the renovation and modernisation of existing buildings. The EC is initially targeting the worst-performing 15% of building stock (requiring an upgrade from energy class G to at least F). While we expect the impact of the new regulation to be limited in our forecast period, we have raised our long-term growth assumptions and changed our sector stance to overweight (neutral).

Free Trial

January 15, 2022 January 15, 2022 1 EN

DnB Markets

Solon Eiendom (No_rec, TP: NOK) - Discontinuing coverage

Discontinuing coverage

Free Trial

January 3, 2022 January 3, 2022 1 EN

The Pebble Group - Two distinct businesses in one

The Pebble Group’s AGM update confirms that trading is in line with FY24 expectations, with attractive opportunities for its two distinct businesses in the large, fragmented promotional products sector. Facilisgroup is a SaaS business, helping North American distributors to optimise their operations, with access to an approved supplier roster. Brand Addition services global brands’ needs for branded product for in-house and external programmes. The well-publicised dip in tech sector marketing spend was a key factor in Pebble’s Q423 outlook revision. Both segments are now well placed to benefit...

8h / 56m 8h / 56m 1 EN

Richard Williamson

Richard Williamson

MotorK - Strong pipeline and cash target reaffirmed

MotorK’s FY23 revenue growth was robust across most regions, with slow growth regions gaining momentum. Q124 revenue fell slightly year-on-year due to delayed delivery contracts, but these are expected to contribute to Q2 sales. Revenue quality improved, with software-as-a-service (SaaS) recurring revenue rising as a share of group revenue in FY23. M&A continues to play a pivotal role in unlocking opportunities across MotorK's markets, providing potential average contract value (ACV) expansion from customers migrating to the platform. While personnel investments for growth swung EBITDA to a lo...

10h / 42m 10h / 42m 1 EN

Sean Conroy

Sean Conroy

Newron Pharmaceuticals - Evenamide notches up another win (study 008A)

Newron Pharmaceuticals has shared positive top-line data for its evenamide programme from its potentially pivotal Phase II/III trial (study 008A) in patients with poorly managed schizophrenia on current antipsychotic therapy, but not considered treatment-resistant. The trial met its primary endpoint of improvement on the Positive and Negative Syndrome Scale (PANSS) score from baseline, and the key secondary endpoint of improvement on the Clinical Global Impression of Severity (CGI-S) scale. Statistical significance was met in both, consolidating the already strong results from the Phase II tri...

10h / 54m 10h / 54m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN